Tag: MD and Stephanie Licata

Poster-Disease-modifying Therapy

Incidence and Severity of Natalizumab Infusion-Related Reactions during Infusion and Postinfusion Observation

Background: Natalizumab, an efficacious treatment for relapsing forms of multiple sclerosis, has an approved dosing of 300 mg infused...

Read More